Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
2012 · PubMed · 3 citations
Z
Z. Jiang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
173
Citations
5
h-index
4
i10-index
Z. Jiang is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 5, co-authored 12 publications.
Papers by this author
worksLBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest
2025 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2025.09.028
571P Adebrelimab plus apatinib and etoposide in the treatment of HER2-negative breast cancer brain metastasis: A phase II study
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.993
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat